Hemorrhagic Hereditary Telangiectasia, HHT
Conditions
Keywords
HHT, VEGF therapy, BEVACIZUMAB
Brief summary
Bevacizumab is widely prescribed for the treatment of severe bleeding related to epistaxis or gastrointestinal bleeding in HHT. We studied the efficacy of bevacizumab on severe bleeding in HHT patients in a randomized study recently published (NCT03227263, J Int Med 2023). In this study, 24 patients were included, 12 patients received bevacizumab and 12 patients received placebo. The duration of patient participation was 6 months, including the 2.5-month treatment period and 3.5 month follow-up after treatment. We describe the evolution of the number of RBC transfused in HHT patients who received bevacizumab during the year after the end of the study.
Interventions
Descriptive study of HHT patients (bevacizumab treatment, number of RBC transfused)
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient included in BABH study
Exclusion criteria
* Patients opposition
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bevacizumab treatment description after end of BABH study | 12 months | Number of patients who received bevacizumab after BABH study. Among patients who received bevacizumab in BABH study: description of re-treatments. In patients who received placebo in BABH study: description of treatments. |
Countries
France
Outcome results
None listed